Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intelligent Bio SolutionsINBS -6.64%48 Return-on-Tangible-Asset is -87.26% as of Mar. 2026. GuruFocus rates INBS with a GF Score™ of 48/100 and a GF Value™ of $2.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Intelligent Bio Solutions ranks worse than 92.51% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Intelligent Bio Solutions's annualizedNet Income for the quarter that ended in Mar. 2026 was $-11.45 Mil. Intelligent Bio Solutions's average total tangible assets for the quarter that ended in Mar. 2026 was $13.12 Mil. Therefore, Intelligent Bio Solutions's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -87.26%.
The historical rank and industry rank for Intelligent Bio Solutions's Return-on-Tangible-Asset or its related term are showing as below:
INBS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -317.42 Med: -135.88 Max: -48.56
Current: -134.88
During the past 9 years, Intelligent Bio Solutions's highest Return-on-Tangible-Asset was -48.56%. The lowest was -317.42%. And the median was -135.88%.
INBS's Return-on-Tangible-Asset is ranked worse than 92.51% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs INBS: -134.88
Intelligent Bio Solutions (NAS:INBS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Intelligent Bio Solutions Return-on-Tangible-Asset Related Terms
Intelligent Bio Solutions Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Intelligent Bio Solutions's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions Return-on-Tangible-Asset Chart
INBS vs ITOC, WOK, BMRA: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Intelligent Bio Solutions's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -87.26% mean?
Intelligent Bio Solutions (INBS) has a Return-on-Tangible-Asset of -87.26% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Intelligent Bio Solutions and its competitors. According to the industry distribution chart, Intelligent Bio Solutions ranks #791 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 92.5%.
Is Intelligent Bio Solutions' Return-on-Tangible-Asset too high?
Intelligent Bio Solutions' current Return-on-Tangible-Asset is -87.26%. Based on the distribution chart, Intelligent Bio Solutions ranks #791 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Intelligent Bio Solutions has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' Return-on-Tangible-Asset compare to ITOC and WOK?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #791 out of 855 companies for Return-on-Tangible-Asset. This places Intelligent Bio Solutions in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Intelligent Bio Solutions and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current Return-on-Tangible-Asset is -87.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.63, compared to a current price of $1.97 — trading 25.1% below its estimated fair value. The current Return-on-Tangible-Asset is -87.26%. Intelligent Bio Solutions' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current Return-on-Tangible-Asset is -87.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued.
The current stock price of $1.97 is trading 25.1% below its estimated GF Value™ of $2.63.
GuruFocus considers Intelligent Bio Solutions to be Modestly Undervalued.
Key valuation signals for INBS:
Return-on-Tangible-Asset: -87.26%
GF Value™: $2.63 vs. price of $1.97 (25.1% below fair value)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
48GF Score
Get the complete analysis for INBS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
